RT Journal Article SR Electronic T1 Leukocytes carrying Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations invade Human Atherosclerotic Plaques JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.07.22.23292754 DO 10.1101/2023.07.22.23292754 A1 Scheidt, Moritz von A1 Bauer, Sabine A1 Ma, Angela A1 Hao, Ke A1 Kessler, Thorsten A1 Vilne, Baiba A1 Wang, Ying A1 Hodonsky, Chani J. A1 Ghosh, Saikat K.B. A1 Mokry, Michal A1 Gao, Hua A1 Kawai, Kenji A1 Sakamoto, Atsushi A1 Kaiser, Juliane A1 Bongiovanni, Dario A1 Fleig, Julia A1 Oldenbuettel, Lilith A1 Chen, Zhifen A1 Moggio, Aldo A1 Sager, Hendrik B. A1 Hecker, Judith S. A1 Bassermann, Florian A1 Maegdefessel, Lars A1 Miller, Clint L. A1 Koenig, Wolfgang A1 Zeiher, Andreas M. A1 Dimmeler, Stefanie A1 Graw, Matthias A1 Braun, Christian A1 Ruusalepp, Arno A1 Leeper, Nicholas J. A1 Kovacic, Jason C. A1 Björkegren, Johan L.M. A1 Schunkert, Heribert YR 2023 UL http://medrxiv.org/content/early/2023/07/26/2023.07.22.23292754.abstract AB Background Leukocyte progenitors derived from clonal hematopoiesis of undetermined potential (CHIP) are associated with increased cardiovascular events. However, the prevalence and functional relevance of CHIP in coronary artery disease (CAD) are unclear, and cells affected by CHIP have not been detected in human atherosclerotic plaques.Methods CHIP mutations in blood and tissues were identified by targeted deep-DNA-sequencing (DNAseq: coverage >3,000) and whole-genome-sequencing (WGS: coverage >35). CHIP-mutated leukocytes were visualized in human atherosclerotic plaques by mutaFISHTM. Functional relevance of CHIP mutations was studied by RNAseq.Results DNAseq of whole blood from 540 deceased CAD patients of the Munich cardIovaScular StudIes biObaNk (MISSION) identified 253 (46.9%) CHIP mutation carriers (mean age 78.3 years). DNAseq on myocardium, atherosclerotic coronary and carotid arteries detected identical CHIP mutations in 18 out of 25 mutation carriers in tissue DNA. MutaFISHTM visualized individual macrophages carrying DNMT3A CHIP mutations in human atherosclerotic plaques. Studying monocyte-derived macrophages from Stockholm-Tartu Atherosclerosis Reverse Networks Engineering Task (STARNET; n=941) by WGS revealed CHIP mutations in 14.2% (mean age 67.1 years). RNAseq of these macrophages revealed that expression patterns in CHIP mutation carriers differed substantially from those of non-carriers. Moreover, patterns were different depending on the underlying mutations, e.g. those carrying TET2 mutations predominantly displayed upregulated inflammatory signaling whereas ASXL1 mutations showed stronger effects on metabolic pathways.Conclusions Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that pro-atherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board and Ethics Committee of the Technical University of Munich, Germany, approved the protocol of MISSION (2018-325-S-KK; 08/22/2018). The use of human STARNET samples has been approved by the Estonian Bioethics and Human Research Committee (Ministry of Social Affairs) (IRB 2771T,17; 12/01/2018) and by the written informed consent of the donor, in accordance with the guidelines and regulations for the use of biological material of human origin. Both studies were conducted in accordance with the provisions of the Declaration of Helsinki and the International Conference on Harmonization guidelines for good clinical practice.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used in this study are available in permanent repositories. Human data from MISSION can be requested by qualified researchers at the German Heart Center Munich from the corresponding author. Human data from STARNET are accessible through the Database of Genotypes and Phenotypes (dbGAP).